Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Cash & Equivalents: 2018-2025

Historic Cash & Equivalents for Whitehawk Therapeutics (WHWK) over the last 8 years, with Sep 2025 value amounting to $162.6 million.

  • Whitehawk Therapeutics' Cash & Equivalents rose 432.47% to $162.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.6 million, marking a year-over-year increase of 432.47%. This contributed to the annual value of $28.7 million for FY2024, which is 54.41% down from last year.
  • According to the latest figures from Q3 2025, Whitehawk Therapeutics' Cash & Equivalents is $162.6 million, which was down 8.24% from $177.2 million recorded in Q2 2025.
  • In the past 5 years, Whitehawk Therapeutics' Cash & Equivalents ranged from a high of $227.6 million in Q1 2025 and a low of $28.7 million during Q4 2024.
  • In the last 3 years, Whitehawk Therapeutics' Cash & Equivalents had a median value of $62.9 million in 2023 and averaged $86.9 million.
  • As far as peak fluctuations go, Whitehawk Therapeutics' Cash & Equivalents surged by 3,244.31% in 2021, and later tumbled by 73.81% in 2022.
  • Quarterly analysis of 5 years shows Whitehawk Therapeutics' Cash & Equivalents stood at $149.0 million in 2021, then crashed by 73.81% to $39.0 million in 2022, then skyrocketed by 61.17% to $62.9 million in 2023, then tumbled by 54.41% to $28.7 million in 2024, then soared by 432.47% to $162.6 million in 2025.
  • Its last three reported values are $162.6 million in Q3 2025, $177.2 million for Q2 2025, and $227.6 million during Q1 2025.